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Abstract
AIM
To report adalimumab (Ada) efficacy on articular-
gastrointestinal disease and health-related quality of life 
(HRQoL) in patients with enteropathic spondyloarthritis 
(ES).
METHODS
A cohort of 52 patients with ES was evaluated in the 
departments of gastroenterology and internal medicine. 
At baseline, all patients underwent assessment by an 
integrated gastro-rheumatologic evaluation of articular 
and gastrointestinal activity, as well patient reported 
outcomes (PROs) of the HRQoL questionnaires. After 
this integrated evaluation and following a specific 
working flowchart, the Ada anti-tumor necrosis factor 
(TNF)-inhibitor was assigned to a cohort of 30 patients 
and its clinical efficacy was evaluated at baseline and 
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after 6-mo and 12-mo treatment by the following 
tests: (1) Ankylosing Spondylitis Disease Activity Score-
C-Reactive Protein (ASDAS-CRP); Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI), Bath 
Ankylosing Spondylitis Functional Index (BASFI) and 
Bath Ankylosing Spondylitis Metrology Index (BASMI) 
for articular activity; (2) Inflammatory Bowel Disease 
Questionnaire (IBDQ), Crohn’s Disease Activity 
Index (CDAI) and partial Mayo (pMayo) score for 
gastrointestinal symptoms and activity; and (3) Health 
Assessment Questionnaire (HAQ), Patient Global 
Assessment (PGA) and Short Form-36 health survey 
(SF-36) questionnaires for PROs of the HRQoL.
RESULTS
Integrated evaluation and management of the pati-
ents affected by ES, carried out simultaneously by 
a gastroenterologist and a rheumatologist, allowed 
clinicians to choose the optimal therapeutic strategy. 
In a cohort of 30 ES patients affected by active 
articular and gastrointestinal disease, or axial active 
articular inflammation, Ada led to fast and sustained 
improvement of both articular and gastrointestinal 
disease activities. In fact, all the clinimetric evaluation 
tests exploring articular or gastrointestinal activity, 
as well as all the HRQoL scores, showed a significant 
improvement having been achieved at the earliest 
(6-mo) assessment. This important clinical improvement 
was maintained at the 12-mo follow-up. Importantly, 
global and gastrointestinal quality of life significantly 
correlated with articular disease activity, providing 
evidence to support that the integrated evaluation is 
the best option to manage patients with ES.
CONCLUSION
Ada treatment, upon multidisciplinary (gastro-
rheumatologic) evaluation, significantly improves both 
articular and gastrointestinal inflammation, thereby 
improving the HRQoL in patients affected by ES. 
Key words: Clinimetric assessment; Patient reported 
outcomes; Inflammatory bowel diseases; Enteropathic 
spondyloarthritis; Tumor necrosis factor-inhibitors; 
Multidisciplinary evaluation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Enteropathic spondyloarthritis (ES) is char-
acterized by articular inflammation in patients with 
inflammatory bowel diseases, such as Crohn’s disease 
or ulcerative colitis. Correct management, especially 
covering both of the two clinical manifestations (gastro-
rheumatologic), remains a challenge. In this study, we 
demonstrated that the integrated gastroenterological 
and rheumatologic evaluation of ES patients achieved 
the best therapeutic approach. In particular, we dem-
onstrated that in a real-life cohort of ES patients, 
the tumor necrosis factor-inhibitor, adalimumab, led 
to fast and sustained improvement of articular and 
gastrointestinal inflammation, with a consequent impr-
ovement in the global and gastrointestinal quality of 
life.
Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri 
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2017; 23(39): 7139­7149  Available from: URL: http://www.
wjgnet.com/1007­9327/full/v23/i39/7139.htm  DOI: http://dx.doi.
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INTRODUCTION
Enteropathic spondyloarthritis (ES) is a seronegative 
spondyloarthropathy (SpA) characterized by the 
presence of articular inflammation in patients aff­
ected by inflammatory bowel diseases (IBDs), 
such as Crohn’s disease (CD) or ulcerative colitis 
(UC)[1,2]. Arthritis is the most frequent extra­intestinal 
manifestation in patients with IBDs[1] and it may 
primarily involve the axial joints, presenting with 
definite ankylosing spondylitis (AS) and/or isolated 
sacroiliitis, or peripheral joints and/or peri­articular 
structures, such as tendons and entheses[3]. The 
articular manifestations significantly affect health­
related quality of life (HRQoL) of ES patients[4].
Although a link between inflammation of the joints 
and gut has been demonstrated[5,6], only half of ES 
patients are actually evaluated by a rheumatologist 
for proper diagnosis and, thus, for an integrated 
therapeutic approach through a coordinated action 
with the treating gastroenterologist[7]. Thus, an inte­
grated clinical evaluation and therapeutic approach 
encompassing both the intestinal and articular features 
in ES patients, will likely be beneficial, particularly for 
the clinical outcomes. It has been demonstrated by 
recent studies that tumor necrosis factor (TNF)­alpha 
inhibitors could be effective therapeutic agents against 
ES[8], but few to date have reported on their real­life 
efficacy in this disease. 
Herein, we have investigated the role of a gastro­
rheumatologic multidisciplinary management and 
therapeutic approach in ES patients through evaluation 
of the efficacy of the TNF-alpha inhibitor adalimumab 
(Ada), assessing the efficacy on both gastrointestinal 
and rheumatologic disease activities and on the 
patient­reported HRQoL.
MATERIALS AND METHODS
Patients and study design
This study was carried out in a cohort of 52 patients 
with ES, including 31 affected by CD (59.6%) and 
21 by UC (40.3%), collectively representing 23.6% 
of the 220 overall patient population with IBD in the 
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Spondyloarthritis in IBD Project (commonly referred to 
as SPIB), described elsewhere[9]. The patients’ clinical 
and laboratory data are shown in Table 1, and the 
patient group is henceforth defined as the “ES­AN” 
cohort (Enteropathic spondyloarthritis from Ancona, 
Italy).
At each clinical observation, both the rheumat­
ologist and the gastroenterologist collaborated in a 
shared session to develop the therapeutic strategy by 
applying a specifically designed algorithm (Figure 1) 
that was mainly based upon gastrointestinal­articular 
disease activity and the site of articular involvement at 
diagnosis (axial or peripheral arthritis). Briefly, the ES-
AN patients were primarily separated into the following 
two groups for comparative analysis: 
Group I (biological drugs-naïve group): This 
group encompassed three treatment subgroups. In 
the axial­ES­AN (Ax­ES­AN) subgroup, patients were 
administered Ada as first­line therapy, due to the 
absolute contraindication for a long­course treatment 
with nonsteroidal anti­inflammatory drugs (NSAIDs) 
7141 October 21, 2017|Volume 23|Issue 39|WJG|www.wjgnet.com
Table 1  Enteropathic spondyloarthritis patient features
ES-AN, n  = 52 ES-AN/Ada, n  = 30
Crohn’s disease:Ulcerative colitis 31 (60):21 (40) 19 (63):11 (37)
   Males:Females 22 (42):30 (58) 17 (57):13 (43)
   Age in years 47.2 ± 14.2 46.2 ± 14.4
   Disease duration of IBD in years 11.3 ± 10.1 8.8 ± 7.9
   Smokers:Ex-smokers 9 (17):20 (38)  
   HLA-B27 positivity 5 (10) 4 (13)
   Prior surgical intervention for IBD 13 (25) 5 (17)
   Previous extra-intestinal disease 6 (11) 5 (17)
   Eritema nodosum   2   1
   Uveitis   3   3
   Pioderma gangrenosum   1   1
Crohn’s disease activity by CDAI
   Inactive 14 (45) 7 (37)
   Moderate 10 (32) 8 (42)
   Moderate-to-Severe 7 (23) 4 (21)
Ulcerative colitis activity by partial Mayo
   Mild 18 (86) 8 (73)
   Moderate 3 (14) 3 (27)
   Severe   0   0
Current medication at baseline
   Non-steroids anti-inflammatory drugs   3   0
   Sulfasalazine   3   2
   Mesalazine 25 12
   Cyclosporine   1   1
   Azathioprine   9   5
   Oral steroids 12   7
   Topical steroids   3   2
   Metotrexate   2   1
   Infliximab   6   4
   Adalimumab   2   0
Spondyloarthritis features   
   Ankylosing spondylitis according to Modified New York Criteria 16 (31) 10 (33)
   Non-radiographic Axial-Spondyloarthritis by ASAS Criteria 13 (25) 10 (33)
   Peripheral- Spondyloarthritis 23 (44) 10 (33)
Type of axial involvement n = 29 n = 20
   Syndesmophytosis 8 (28) 6 (30)
   Bamboo spine 2 (7) 2 (10)
   Sacroiliitis by MRI and/or X-ray 29 (100) 20 (100)
Type of articular involvement in Crohn’s disease n = 31 n = 19
   Axial 16 (52) 11 (58)
   Axial and peripheral   4   3
   Peripheral only 15 (48) 8 (42)
   Enthesitis 9 (29) 5 (26)
Type of articular involvement in ulcerative colitis n = 21 n = 11
   Axial 13 (62) 9 (82)
   Axial and peripheral   9   5
   Peripheral only 8 (38) 2 (18)
   Enthesitis 4 (19) 2 (18)
Data are presented as n, n (%) or mean ± SD. CDAI: Crohn’s Disease Activity Index; ES-AN: Patient cohort with enteropathic spondyloarthritis from 
the SPIB Program, Ancona, Italy; ES-AN/Ada: Patients of the ES-AN cohort treated with adalimumab; IBD: Inflammatory bowel disease; NSAID: Non-
steroidal anti-inflammatory drug. 
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once every 2 wk. 
Study measures and evaluation
All patients of the ES­AN cohort were assessed for 
clinical disease activity and HRQoL (Table 2). Briefly, 
articular (SpA) disease activity was assessed by the 
Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)[10] and the Ankylosing Spondylitis Disease 
Activity Score­C­Reactive Protein (ASDAS­CRP) 
calculation[11]; gastrointestinal (IBD) disease activity 
was assessed with the Crohn’s Disease Activity Index 
(CDAI) for CD[12] and the partial Mayo (pMAYO) score 
for UC[13].
Patient­reported outcomes (PROs) were assessed 
with tests specific for articular­related symptoms 
[i.e. the Bath Ankylosing Spondylitis Functional Index 
(BASFI)][14] and gastrointestinal­related symptoms 
[i.e. the Inflammatory Bowel Disease Questionnaire 
(IBDQ)][15]. Global wellness was assessed by use of 
the Health Assessment Questionnaire (HAQ), Patient 
Global Assessment (PtGA), and the Short Form­36 
health survey (SF­36)[16].
Statistical analysis
Endpoints of this study were the disease activity 
indexes at baseline and at 6­mo and 12­mo follow­
ups. Variables are presented as mean ± standard 
deviation. Comparisons between groups at baseline 
in case of IBD. In the peripheral­ES­AN (Per­ES­AN) 
subgroup, patients with active IBD or who were non­
responders to a short course of corticosteroids (not 
more than 3 mo) or NSAIDs (not more than 2 wk) 
were administered either a disease­modifying anti­
rheumatic drug (DMARD), such as either methotrexate 
(MTX) or sulfasalazine (SSZ), or Ada if erythrocyte 
sedimentation rate (ESR) was > 30 mm/h and/or 
C­reactive protein (CRP) concentration was > 0.5 
mg/dL and/or in the presence of polyarticular inflam-
matory involvement. In the Per­ES­AN in inactive 
IBDs subgroup, patients were administered steroids 
or DMARDs, depending on count number of inflamed 
joints and systemic inflammation (evaluated by ESR 
and/or CRP). 
Group II (TNF inhibitor-treated group): This 
group also encompassed three treatment subgroups. 
For the first, the Per-ES-AN consisting of patients with 
still active IBD were switched to another TNF­inhibitor 
(Ada). For the second, the Per­ES­AN consisting of 
patients with IBD in remission were administered a 
DMARD in addition to the TNF­inhibitor already in use. 
For the third, the Ax­ES­AN patients were switched to 
Ada, regardless of IBD activity.
In all patients, the TNF­inhibitor Ada was used as 
recommended for IBD treatment: 160 mg in the first 
week, 80 mg for the next 2 wk, and thereafter 40 mg 
Figure 1  Therapeutic algorithm of the ES-AN patient cohort at the time of entry into the study. A: ES patients biological drugs-naïve were treated depending on 
IBD activity and site of the articular involvement, as follows: a) Ax-ES-AN with Ada as the TNF-inhibitor in first-line therapy, due to the absolute contraindication for a 
long-course treatment with NSAIDs in cases of IBDs; b) Per-ES-AN in cases of active IBD and in those patients who were non-responders to short-course corticosteroid 
treatment (not > 3 mo) or NSAIDs (not > 2 wk), with DMARD (methotrexate or sulfasalazine), or in cases of ESR > 30 mm/h and/or CRP > 0.5 mg/dL, and polyarticular 
inflammatory involvement with Ada; c) Per-ES-AN in inactive IBD, with steroids or DMARDs, depending on the number of inflamed joints and systemic inflammation 
(evaluated by ESR and/or CRP); B: ES patients already in treatment with infliximab for the IBD. In the ES-AN patients already treated with IFX: a) Per-ES-AN with 
active IBD were switched to Ada; b) Per-ES-AN with IBD in remission received a DMARD in addition to the IFX already in use; c) Ax-ES-AS were switched to Ada, 
regardless of IBD activity. Dashed line: Patients refractory to therapy. Therapeutic doses: DMARDs were prescribed at the standard dose regimens (salazopyrine 2 gr 
bid; methotrexate 10-20 mg once a week); Ada was used following the therapeutic dosage and indications for IBDs (160 mg at d 1 and 80 mg after 2 wk, followed by 
40 mg every 2 wk). Ada: Adalimumab; AX-ES-AN: Patients with axial spondyloarthritis in the ES-AN cohort; CRP: C-reactive protein; ES: Enteropathic spondyloarthritis; 
ES-AN: Patients affected by ES in the Ancona’s cohort; ESR: Erythrocyte sedimentation rate: DMARD: Disease modifying anti-rheumatic drug; IBD: Inflammatory bowel 
disease; NSAID: Non-steroidal anti-inflammatory drug; Per-ES-AN: Patients with peripheral spondyloarthritis in the ES-AN cohort.
Enteropathic spondyloarthritis
Native, n  = 39
Active IBD         IBD in remission
Peripheral        Axial             Axial                 Peripheral
SpA            SpA               SpA                     SpA
Salazopyrin 
or 
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IBD refractory
to conventional
therapy at least 
for 3 mo
+ Anti-TNF-alfa 
(used as recommended 
for IBD treatment)
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or 
Mtx
A
Enteropathic spondyloarthritis (ES)
in-treatment with anti-TNF-alfa, n  = 13
Active IBD                     IBD in remission
Peripheral           Axial                  Axial                    Peripheral
SpA                SpA                    SpA                        SpA
Salazopyrin 
or 
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to therapy and
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least for 5 mo
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anti-TNF-alfa 
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for IBD treatment)
B
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and between baseline and subsequent assessments 
were performed, respectively, with unpaired and paired 
Student’s t­tests. Correlations between variables were 
assessed using Pearson’s correlation coefficient. Data 
were analyzed using the SPSS software (v22.0; IBM 
SPSS Statistics for Windows, Armonk, NY, United 
States).
RESULTS
Baseline assessment of the patients
In the ES­AN cohort, 29 (57.6%) patients were 
affected by predominant axial SpA (Ax­ES­AN) and 
23 (42.3%) by peripheral SpA (Per­ES­AN) (Table 1). 
Only 5 patients showed positivity for human leukocyte 
antigen­B27 (9.6%), including 4 affected by Ax­ES­
AN and 1 by Per­ES­AN. Sacroiliitis was found in all 
the Ax-ES-AN patients, but 17 (55%) patients fulfilled 
the Modified New York Criteria for AS, whereas 13 
(45%) were affected by non­radiographic axial­SpA[2]. 
Syndesmophytosis was found in 8 (27.6%) of the Ax­
ES­AN patients at different levels, but only 2 (6.9%) 
presented a bamboo spine radiologic feature at 
baseline. Concurrent peripheral arthritis and enthesitis 
were present in about half of the Ax­ES­AN patients 
(44.8%).
According to the established criteria, IBD was 
active in 63.2% of the CD patients and in 98% of 
the UC patients, although the degrees of activity 
varied. At baseline, no differences were observed 
between the axial and peripheral spondyloarthritis 
patients and between the CD and UC patients for the 
articular disease activity (BASDAI, ASDAS­CRP) and 
the PROs [IBDQ, BASFI, PtGA, HAQ, SF­36 Physical 
Component Score (PCS) and Mental Component Score 
(MCS)] (data not shown). Following findings from the 
integrated evaluation and according to the algorithm 
presented in Figure 1, the criteria employed in our 
study to guide the therapeutic choice were (1) the 
presence and/or absence of active IBD (evaluated by 
both the gastroenterologist and by the results of the 
gastrointestinal tests and PROs); and (2) the site of 
articular involvement (axial or peripheral joints). Thus, 
Ada was assigned to a cohort of 30 patients, henceforth 
defined as the ES-AN/Ada cohort. Among this cohort, 
4 were switched from infliximab for inefficacy, and the 
total was comprised of 20 patients with Ax­ES­AN and 
10 patients with Per­ES­AN (Table 1).
Evaluation of articular and gastrointestinal disease 
activity
In most of the ES­AN/Ada patients, articular disease 
activity, as assessed by ASDAS­CRP and BASDAI, was 
significantly improved at 6­mo compared to baseline 
Table 2  Clinimetric test for articular-gastrointestinal activity and patient reported outcomes of health-related quality of life
Test Items and interpretation
Bath Ankylosing Spondylitis 
Disease Index[10]
6 items: (1) fatigue, (2) back pain, (3) peripheral pain/swelling, (4) discomfort at pressure, (5) morning discomfort, and (6) 
duration of morning stiffness;
 Range from 0 to 10, with lower number representing less severe disease activity;
Score > 4 = active disease.
Ankylosing Spondylitis 
Disease Activity Score-C-
Reactive Protein[11]
5 items: (1) back pain, (2) morning stiffness, (3) patient global, (4) peripheral pain/swelling, and (5) C-reactive protein;
 Score < 1.3 = inactive disease; Score 1.3 to < 2.1 = moderate activity; Score 2.1 to ≤ 3.5 = high activity; Score > 3.5 = very 
high activit; Change ≥ 1.1 = clinically important improvement; Change ≥ 2.0 = major improvement.
Crohn’s Disease Activity 
Index[12]
8 items: (1) liquid stools, (2) abdominal pain, (3) general well-being, (4) extra-intestinal manifestations (including 
arthralgia), (5) use of anti-diarrheals, (6) abdominal masses, and (7) hematocrit, 8) weight;
 Final score is the sum of items, weighted by different factors;
Score < 150 = non-active disease; Score > 150 = active disease; Score > 450 = extremely severe disease.
Partial MAYO score[13] 3 items: (1) stool frequency, (2) rectal bleeding, and (3) physician global assessment;
Range from 0 to 9;
Score < 2 = disease remission; Score 2-4 = mild disease activity; Score 5-7 = moderate disease activity; Score > 7 = severe 
disease activity.
Bath Ankylosing Spondylitis 
Functional Index[14]
10 questions designed to determine the degree of functional limitation;
Final score ranges from 0 to 10, with lower score indicating less functional limitation.
Inflammatory Bowel Disease 
Questionnaire[15]
32 questions divided into 4 subscales: (1) bowel symptoms (10 questions); (2) systemic symptoms, including sleep 
disorders and fatigue (5 questions); (3) emotional function, such as depression, aggression and irritation (12 questions); 
and (4) social function, meaning the ability to participate in social activities and to work (5 questions);
The patient is invited to choose from 1 to 7 for every question;
Total score ranges from 32 to 224 points, with lower scores reflecting worse quality of life.
Patient Global Assessment 
(PtGA)
Collected on a numeric rating scale ranging from 0 to 10 for the question asking the patient: “Considering all the ways 
your disease affects you, how much do you think is active today?”
Short Form-36 health 
survey[16]
Generic health status instrument with 8 domains: (1) physical function, (2) body pain, (3) role limitations–physical, (4) 
general health, (5) vitality, (6) social function, (7) role limitations–emotional, and (8) mental health; 
Greater scores reflect better health status; 
Summarized in two summary scores defined as the (1) physical component score (Sf-36/PCS) and (2) mental component 
score (Sf-36/MCS).
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(ASDAS­CRP: 3.2 ± 0.8 vs 1.9 ± 0.6, P < 0.001; 
BASDAI: 5.5 ± 1.7 vs 3.2 ± 1.8, P < 0.001). A major 
clinical improvement (ASDAS change of ≥ 2) occurred 
in 21% and an important clinical improvement (ASDAS 
change of ≥ 1.1) occurred in 52% (Figure 2A). The 
improvement of articular disease was significant in both 
the axial and the peripheral subgroups of patients (P < 
0.001 for both comparisons). The clinical improvement 
at the articular level was maintained at the 12­mo 
examination (Figure 2A).
Regarding the gastrointestinal disease activity, in 
the CD patients the treatment led to a fast, consistent 
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Figure 2  Evaluation of articular-gastrointestinal disease activity and HRQoL in the ES-AN patient cohort at baseline and after adalimumab therapy. All data 
of the ES-AN patients were collected at baseline (T0), and after 6 mo (T6) and 12 mo (T12) of therapy. A: Evaluation of the articular disease activity with BASDAI or 
ASDAS-CRP (Left), and of the gastrointestinal disease activity by CDAI for CD and pMAYO for UC (Right); B: Evaluation of PROs of gastrointestinal disease activity 
by IBDQ (Left), and of global wellness by the PtGA (Right). aP < 0.05, bP < 0.01, eP < 0.001. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score/C-Reactive 
Protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CDAI: Crohn’s Disease Activity Index; ES: Enteropathic spondyloarthritis; ES-AN: Patients 
affected by ES in the Ancona’s cohort; HRQoL: Health-Related Quality of Life; IBDQ: Inflammatory Bowel Disease Questionnaire; pMAYO: Partial Mayo score; PROs: 
Patient reported outcomes. 
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and significant improvement of the gastrointestinal 
symptoms at 6 mo, as assessed by the CDAI score 
(181.3 ± 93.2 vs 112.3 ± 63.0, P < 0.01; Figure 
2A), and maintained at 12 mo, when the clinical 
remission was observed in almost all patients (Figure 
2A). In parallel, a significant clinical improvement 
was observed also in the UC patients, as shown by 
the decrease of the pMAYO score at the 6­mo and 
12­mo examinations (Figure 2A). All the values and 
comparisons are detailed in Table 3.
Evaluation of the HRQoL
ES-AN/Ada patients reported significant improvement, 
from baseline to 6 mo, in the IBDQ (145.3 ± 36.8 vs 
172.8 ± 36.7, P < 0.01), PtGA (61.1 ± 20.6 vs 35.6 ± 
19.1, P < 0.01; Figure 2B) and HAQ (4.8 ± 7.9 vs 2.0 
± 4.2, P < 0.05) scores, and this improvement was 
maintained at 12 mo. Moreover, regarding the PROs 
impacting articular function and global health wellness, 
significant improvements were observed from baseline 
to 6 mo in the BASFI (3.2 ± 2.4 vs 1.8 ± 1.4, P < 0.01), 
Sf­36/PCS (42.2 ± 9.7 vs 48.4 ± 7.3, P < 0.01) and 
Sf­36/MCS scores (35.4 ± 10.9 vs 39.4± 8.8, P < 0.05; 
Figure 2C); again, the improvements were maintained 
at 12 mo. The improvement of all the scores for PROs 
was similar in both the Ax­ES­AN/Ada and Per­ES­AN/
Ada subgroups at each follow­up observation. All the 
values and comparisons are detailed in Table 3.
Correlations between variables
At baseline, it is noteworthy that a consistent signi­
ficant correlation was observed between the IBDQ test 
(specific for the evaluation of the PROs related to the 
gastrointestinal disease activity) and the clinimetric 
scores of articular activity, as assessed by ASDAS­CRP 
(Figure 3A), BASDAI, and with most of the PROs of the 
HRQoL, as assessed by Sf­36/MCS and CDAI (Table 
4). Moreover, articular disease activity at baseline 
was significantly correlated with worse results in the 
HRQoL tests, as shown by the Sf­36/PCS and Sf­36/
MCS scores (Table 4). After 12 mo of Ada treatment, 
improvement of the articular activity (ASDAS­CRP) 
correlated significantly with decrease in the gastroin-
testinal disease activity scores, as assessed by CDAI 
in the CD patients (Figure 4A) and IBDQ in all of the 
patients, and with most of the PROs of the HRQoL, as 
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Figure 3  Correlations between articular and gastrointestinal disease activity and HRQoL scores in the ES-AN patient cohort at baseline. A: Correlation 
between the PROs of gastrointestinal disease activity (assessed by IBQD) scores and SF-36 summary scores (assessed by PCS and MCS) with articular activity 
scores (assessed by ASDAS-CRP); B: Correlation of the articular function (assessed by BASFI with SF-36/PCS); C: Correlation of the IBDQ with crohn’s disease 
gastrointestinal disease activity (assessed by CDAI) and the SF-36/MCS. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; CDAI: 
Crohn’s Disease Activity Index; ES: Enteropathic spondyloarthritis; ES-AN: Patients affected by ES in the ancona’s cohort; HRQoL: Health-Related Quality of Life; 
IBDQ: Inflammatory Bowel Disease Questionnaire; PROs: Patient reported outcomes; SF-36/MCS: Summary of “Mental Component Score” of the Short Form-36 
health survey; SF-36/PCS: Summary of “Physical Component Score” of the Short Form-36 health survey.
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shown by the Sf­36/PCS (r = ­0.30, P < 0.05) and 
Sf­36/MCS (r = ­0.41, P < 0.01) scores (Figure 2C), as 
well as the BASFI (r = 0.57, P < 0.001), PtGA (r = 0.37, 
P < 0.01) and HAQ (r = 0.28, P < 0.05) scores. All the 
correlations for the values at 12­mo examination are 
detailed in Table 4.
Tolerability
Ada was well tolerated throughout the follow­up 
period. Side effects reported included recurrent upper 
respiratory tract infections (n = 2), bothersome hair 
loss (n = 1), and widespread itch (n = 2); but none 
necessitated suspension of the treatment. One patient 
suffered from a serious infection (axillary suppurative 
hidradenitis) that required prolonged antibiotic treat­
ment. The other minor side effects reported were 
headache and fatigue.
DISCUSSION
The association between SpAs and IBDs has been 
known since the beginning of the last century[17]. 
However, gastroenterologists and rheumatologists 
continue to carry out their clinical evaluations and 
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Figure 4  Correlations between articular and gastrointestinal disease activity and HRQoL scores in the ES-AN patient cohort after adalimumab therapy. A: 
Evaluation data collected for the 30 ES-AN/Ada patients after 12 mo of therapy, showing correlation between gastrointestinal and articular disease activity in Crohn’s 
disease patients (assessed by CDAI) and ASDAS-CRP respectively, and between ASDAS-CRP and SF-36 summary scores (PCS and MCS); B: Correlation between 
CDAI and articular function (assessed by BASFI); C: Correlation between the gastrointestinal quality of life (assessed by IBDQ) and CDAI and SF-36/MCS. ASDAS-
CRP: Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; CDAI: Crohn’s Disease Activity Index; ES-AN: Patients affected by ES in the Ancona’s cohort; 
ES-AN/Ada: Patients of the ES-AN cohort treated with adalimumab; HRQoL: Health-Related Quality of Life; IBDQ: Inflammatory Bowel Disease Questionnaire; SF-36/
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survey; Sf-36/PCS: Summary of “Physical Component Score” of the short form-36 health survey; PROs: Patient reported outcomes.
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Table 3  Scores of the clinimetric test for articular-
gastrointestinal activity and patient reported outcomes of 
health-related quality of life
Baseline T6 T12
CDAI, n = 19 181.3 ± 93.2 112.3 ± 63.0b 82.7 ± 48.7b
pMAYO, n = 11 3.27 ± 1.79 1.81 ± 1.07a 1.63 ± 1.43a
IBDQ 145.3 ± 36.8 172.8 ± 36.7e 180.7 ± 33.0e
BASDAI 5.5 ± 1.7 3.2 ± 1.8e 3.3 ± 1.7e
BASFI 3.2 ± 2.4 1.8 ± 1.4e 2.0 ± 1.3a
ASDAS-CRP 3.2 ± 0.8 1.9 ± 0.6e 1.9 ± 0.6e
PtGA 61.1 ± 20.6 35.6 ± 19.1b 33.0 ± 19.1b
HAQ 4.7 ± 8.5 2.0 ± 4.2a 1.6 ± 3.5a
Sf-36/PCS 42.2 ± 9.7 48.4 ± 7.2e 48.5 ± 7.3b
Sf-36/MCS 35.4 ± 10.9 39.4 ± 8.8a 41.4 ± 9.7a
CRP in mg/dL 2.7 ± 3.7 0.8 ± 1.2a 0.5 ± 0.6a
 aP < 0.05, bP < 0.01, eP < 0.001. ASDAS-CRP: Ankylosing Spondylitis 
Disease Activity Score-C-Reactive Protein; BASDAI: Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis 
Functional Index; CDAI: Crohn’s Disease Activity Index; CRP: C-Reactive 
Protein; pMAYO: partial Mayo score; HAQ: Health Assessment 
Questionnaire; IBDQ: Inflammatory Bowel Disease Questionnaire; PtGA: 
Patient Global Assessment; SF-36/MCS: Summary of “Mental Component 
Score” of the Short Form-36 health survey; SF-36/PCS: Summary of 
“Physical Component Score” of the Short Form-36 health survey; T6 and 
T12: Results of the evaluation after 6 mo and 12 mo of treatment with 
adalimumab respectively.
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the therapeutic management of these diseases, now 
known collectively as ES, independently. In this regard, 
the different clinical guidelines employed by the two 
medical specialists may lead to different therapeutic 
decisions for the same clinical scenario, ultimately 
harboring potential for different clinical outcomes of 
the disease. A critical issue in the clinical management 
of ES is the correct therapeutic choice, and an im­
portant role has emerged recently for the TNF­alpha 
inhibitors in this regard. Infliximab was the first TNF-
alpha inhibitor used in ES[18], but Ada has recently 
been applied to ES patients affected by CD and has 
achieved rates of clinical remission up to 50%[19].
To our knowledge, this is the first study demon­
strating the efficacy of the integrated gastrorhe­
umatologic approach for evaluation and therapeutic 
management of ES patients, with efficacy evidenced 
through assessments of disease activity and HRQoL over 
a 12­mo period. As dictated by our operative algorithm, 
both the gastroenterologist and the rheumatologist 
evaluated each of the patients in the study cohort, 
with both of the specialists collaborating to choose 
the optimal therapy. This integrated multidisciplinary 
approach, therefore, considered the gastrointestinal 
and articular disease activities simultaneously and, 
most importantly in the latter case, the site of articular 
inflammation (axial or peripheral). Thus, for example, 
in the case of axial spondyloarthritis, the therapy with 
anti­TNF­alpha inhibitors was mandatory, following the 
latest rheumatologic indications[20].
Since only few studies in the literature have so 
far evaluated the efficacy and safety of anti­TNF­
alpha in ES, we employed the up and coming Ada 
treatment in our study. The results indicated that in 
ES patients, regardless of IBD type and/or site of 
articular involvement, Ada significantly improves the 
inflammation states of both the joints (assessed by 
ASDAS­CRP and BASDAI) and gut (assessed by CDAI 
or pMAYO score), as well as the HRQoL. Moreover, 
the benefits were already observable at 6 mo and the 
improvements were maintained at 12 mo. Ada also 
consistently improved not only the physical function in 
almost all ES patients (assessed by PtGA, BASFI, HAQ 
and Sf­36/PCS) but also their psychological function 
(assessed by Sf­36/MCS and IBDQ), from baseline to 
6 mo. 
It is noteworthy that in our study the strong 
linear relationship between articular­gastrointestinal 
disease activity and the PROs confirms the strong 
link between gut and joint inflammations. In fact, the 
IBDQ (specific for the gastrointestinal­related quality 
of life) strongly correlated with results of the clinimetric 
tests of articular activity (ASDAS­CRP, BASDAI and 
BASFI); additionally, the articular disease activity 
(assessed by ASDAS­CRP) strongly correlated with all 
of the PROs studied, even those specific for IBDs. To 
Table 4  Correlations between the scores of clinimetric tests for articular-gastrointestinal activity and patient reported outcomes of 
health-related quality of life scores 
CDAI pMAYO IBDQ BASDAI BASFI ASDAS-CRP PtGA HAQ Sf-36/ PCS Sf-36/ MCS CRP
At baseline
   CDAI 1 1 -0.57b 0.19 0.29 0.21 0.14 0.12 -0.24 -0.33 0.35
   pMAYO 1 1 -0.48a 0.34 0.38 0.37 0.15 0.18 -0.14 -0.11 0.28
   IBDQ -0.57b -0.48a 1 -0.38b -0.34a -0.52b -0.26 -0.19 0.27 0.67b -0.26
   BASDAI 0.19 0.34 -0.38b 1 0.64b 0.69b 0.24 0.26 -0.22 -0.31a 0.00
   BASFI 0.29 0.38 -0.34a 0.64b 1 0.57b 0.37b 0.36b -0.44b -0.15 0.37b
   ASDAS-CRP 0.21 0.37 -0.52b 0.69b 0.57b 1 0.37b 0.36b -0.30a -0.41b 0.32a
   PtGA 0.14 0.15 -0.26 0.24 0.37b 0.37b 1 0.22 -0.14 -0.22 0.14
   HAQ 0.12 0.18 -0.19 0.26 0.36b 0.36b 0.22 1 -0.46b -0.03 0.07
   Sf-36/PCS -0.24 -0.14 0.27 -0.22 -0.44e -0.30a -0.14 -0.46b 1 0.05 -0.13
   Sf-36/MCS -0.33 -0.11 0.67b -0.31a -0.15 -0.41b -0.22 -0.03 0.05 1 -0.08
After 12 mo of therapy with adalimumab (ES-AN/Ada cohort)
   CDAI 1 1 -0.83b 0.16 0.56a 0.54a 0.53a 0.53a -0.71b -0.67b 0.75b
   pMAYO 1 1 -0.51 0.18 0.49 0.17 0.56 -0.29 -0.14 -0.25 0.6
   IBDQ -0.83b -0.51 1 -0.23 -0.56b -0.55b -0.61b -0.36a 0.53b 0.66b -0.52b
   BASDAI 0.16 0.18 -0.23 1 0.58b 0.68b 0.51b 0.39a -0.52b -0.11 -0.14
   BASFI 0.56a 0.49 -0.56b 0.58b 1 0.56b 0.64b 0.54b -0.52b -0.45a 0.16
   ASDAS-CRP 0.54a 0.17 -0.55b 0.68b 0.56b 1 0.67b 0.38a -0.62b -0.41a 0.31
   PtGA 0.53a 0.56 -0.61b 0.51b 0.64b 0.67b 1 0.51b -0.37a -0.59b 0.26
   HAQ 0.53a -0.29 -0.36a 0.39a 0.54b 0.38a 0.51b 1 -0.47b -0.40a 0.10
   Sf-36/PCS 1 1 -0.83b 0.16 0.56a 0.54a 0.53a 0.53a -0.71b -0.67b 0.75b
   Sf-36/MCS 1 1 -0.51 0.18 0.49 0.17 0.56 -0.29 -0.14 -0.25 0.60
   CRP -0.83b -0.51 1 -0.23 -0.56b -0.55b -0.61b -0.36a 0.53b 0.66b -0.52b
Correlations between variables were assessed in the 30 patients with enteropathic spondyloarthritis from Ancona, Italy, at baseline and after 6 mo (data 
not shown) and 12 mo of therapy with adalimumab (ES-AN/Ada), using Pearson’s correlation coefficient; aP < 0.05, bP < 0.01. ASDAS-CRP: Ankylosing 
Spondylitis Disease Activity Score-C-Reactive Protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis 
Functional Index; CDAI: Crohn’s Disease Activity Index; CRP: C-Reactive Protein; HAQ: Health Assessment Questionnaire; IBDQ: Inflammatory Bowel 
Disease Questionnaire; pMAYO: partial Mayo score; PtGA: Patient Global Assessment; SF-36/MCS: Summary of “Mental Component Score” of the Short 
Form-36 health survey; SF-36/PCS: Summary of “Physical Component Score” of the Short Form-36 health survey.
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the contrary, however, at baseline the gastrointestinal 
disease activity scores (except for those of the IBDQ) 
did not correlate well with the other variables, but at 
12 mo of therapy the CDAI correlated with most of 
the articular and PROs of HRQoL. This latter finding 
may be consequent to the different degrees of disease 
activities reported by the patients at baseline, which, 
after the treatment, tend to be globally ameliorated 
both at the gastrointestinal and articular levels.
Thus, since only the ASDAS­CRP test proved to 
be the most reliable in all patients in our study, we 
think that it should be necessary to develop composite 
scores and HRQoL questionnaires specific and suitable 
for ES patients at diagnosis, similar to those developed 
for other multidisciplinary diseases, such as psoriatic 
arthritis[21]. In conclusion, in our work that was carried 
out in a real­life cohort of a significant number of 
ES patients, we demonstrated that Ada produced 
a fast and significant improvement of both the gas­
trointestinal and articular scores of disease activity 
and, moreover, of the HRQoL. This clinical result 
was achieved by employing an integrated outpatient 
clinic specific for ES patients, as recently endorsed, 
particularly with regard to early diagnosis[22,23]. The 
integrated approach provided the optimal management 
of both the multidisciplinary clinical evaluation and the 
therapy of these patients. Further studies are certainly 
warranted to assess the long­term outcomes, and 
tolerability, of Ada and other TNF­alpha inhibitors in 
patients affected by ES.
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